Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherANALGESIA AND DRUGS OF ABUSE

ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: A Novel, Orally Effective Antinociceptive Agent Acting viaNeuronal Nicotinic Acetylcholine Receptors: II. In VivoCharacterization

Anthony W. Bannon, Michael W. Decker, Peter Curzon, Michael J. Buckley, David J. B. Kim, Richard J. Radek, John K. Lynch, James T. Wasicak, Nan-Horng Lin, William H. Arnold, Mark W. Holladay, Michael Williams and Stephen P. Arneric
Journal of Pharmacology and Experimental Therapeutics May 1998, 285 (2) 787-794;
Anthony W. Bannon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael W. Decker
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Curzon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Buckley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. B. Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard J. Radek
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John K. Lynch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James T. Wasicak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nan-Horng Lin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William H. Arnold
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark W. Holladay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Williams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen P. Arneric
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The antinociceptive effects of ABT-594, a novel nicotinic acetylcholine receptor (nAChR) ligand, were examined in rats in models of acute thermal (hot box) and persistent chemical (formalin test) pain. Also, the effects of ABT-594 treatment on motor function and electroencephalogram (EEG) were determined. In the hot box and formalin test (i.e., phase 1 and 2), acute treatment with ABT-594 (0.03, 0.1 and 0.3 μmol/kg i.p.) produced significant dose-dependent antinociceptive effects. In the hot box, the efficacy of ABT-594 was maintained after a repeated dosing paradigm (5 days b.i.d. i.p.). ABT-594 was fully efficacious in the formalin test when administered before formalin, and also retained significant efficacy (0.3 μmol/kg i.p.) when administered after formalin injection. The antinociceptive effects of ABT-594 in the hot box and formalin tests were attenuated by pretreatment with the nAChR antagonist, mecamylamine, and in animals treated with the nAChR antagonist, chlorisondamine, given centrally (10 μg/rat i.c.v. 5 days before), but not in animals pretreated with the opioid receptor antagonist, naltrexone. Acute treatment with ABT-594 produced an initial decrease in open-field locomotor activity, which was absent in animals dosed repeatedly (5 days b.i.d.) with ABT-594. Also, acute treatment with ABT-594 decreased body temperature and decreased the amount of time the animals could maintain balance in an edge-balance test. These effects were no longer present in animals dosed repeatedly with ABT-594. At antinociceptive doses, ABT-594 produced activation of free running EEG in contrast to the sedative-like effects of morphine. Full antinociceptive efficacy was maintained in both the hot box and formalin tests after oral administration, whereas the effects on motoric performance were attenuated. In conclusion, these data demonstrate that ABT-594 is a potent antinociceptive agent with full efficacy in models of acute and persistent pain and that these effects are mediated predominately by an action at central neuronal nAChRs. In addition, antinociceptive effects were maintained after repeated dosing, whereas effects of ABT-594 on motor and temperature measures were attenuated in animals treated repeatedly with ABT-594. Thus, compounds acting at nAChRs may represent a novel approach for the treatment of a variety of pain states.

Footnotes

  • Send reprint requests to: Michael W. Decker, Ph.D., Dept. 47W, Bldg. AP-9A LL, 100 Abbott Park Rd., Abbott Park, IL 60064-3500.

  • ↵1 Current Address: Amgen Inc., Thousand Oaks, CA 91320.

  • ↵2 Current Address: DuPont-Merck Pharmaceutical, Wilmington, DE 19880-0400.

  • Abbreviations:
    NSAIDS
    nonsteroidal antiinflammatory drugs
    nAChRs
    nicotinic acetylcholine receptors
    sal
    saline
    mec
    mecamylamine
    ntx
    naltrexone
    chlor
    chlorisondamine
    nic
    nicotine
    EEG
    electroencephalogram
    FFT
    Fast Fourier Transform
    REM
    rapid eye movement
    i.c.v.
    intracerebroventricular
    • Received September 12, 1997.
    • Accepted February 9, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 285, Issue 2
1 May 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: A Novel, Orally Effective Antinociceptive Agent Acting viaNeuronal Nicotinic Acetylcholine Receptors: II. In VivoCharacterization
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherANALGESIA AND DRUGS OF ABUSE

ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: A Novel, Orally Effective Antinociceptive Agent Acting viaNeuronal Nicotinic Acetylcholine Receptors: II. In VivoCharacterization

Anthony W. Bannon, Michael W. Decker, Peter Curzon, Michael J. Buckley, David J. B. Kim, Richard J. Radek, John K. Lynch, James T. Wasicak, Nan-Horng Lin, William H. Arnold, Mark W. Holladay, Michael Williams and Stephen P. Arneric
Journal of Pharmacology and Experimental Therapeutics May 1, 1998, 285 (2) 787-794;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OtherANALGESIA AND DRUGS OF ABUSE

ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: A Novel, Orally Effective Antinociceptive Agent Acting viaNeuronal Nicotinic Acetylcholine Receptors: II. In VivoCharacterization

Anthony W. Bannon, Michael W. Decker, Peter Curzon, Michael J. Buckley, David J. B. Kim, Richard J. Radek, John K. Lynch, James T. Wasicak, Nan-Horng Lin, William H. Arnold, Mark W. Holladay, Michael Williams and Stephen P. Arneric
Journal of Pharmacology and Experimental Therapeutics May 1, 1998, 285 (2) 787-794;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Protein Kinase A Maintains Cellular Tolerance toMu Opioid Receptor Agonists in Hypothalamic Neurosecretory Cells with Chronic Morphine Treatment: Convergence on a Common Pathway with Estrogen in Modulating Mu Opioid Receptor/Effector Coupling
  • Structure-Activity Relationships of Indole- and Pyrrole-Derived Cannabinoids
  • Effect of COX-1 and COX-2 Inhibition on Induction and Maintenance of Carrageenan-Evoked Thermal Hyperalgesia in Rats
Show more ANALGESIA AND DRUGS OF ABUSE

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics